Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 15Fluorouracil 13Bevacizumab 13Leucovorin 10Capecitabine 8Folfox protocol 7Irinotecan 6IFL protocol 4Cetuximab 4Folic Acid 3Aspirin 3atezolizumab 2XELOX 2Surgical Procedures, Operative 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Chemotherapy, Adjuvant 2trifluridine tipiracil drug combination 1trametinib 1titanium silicide 1sulindac sulfone 1spartalizumab 1sacituzumab govitecan 1regorafenib 1raltitrexed 1pertuzumab 1irinotecan sucrosofate 1folfirinox 1envafolimab 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Colorectal Neoplasms × titanium silicide × Clear all
NCT00284258 2012-11-02

Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

Taiho Pharmaceutical Co., Ltd.

Phase 2/3 Completed
426 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡